|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Investigations |
Departments of Surgery (J.A.Q., D.A.R., A.H.F., J.N.R., J.H.S., J.V., S.G., A.W., H.S., D.D.B., S.T.-U., M.L.A., S.J., D.A., K.Z., C.B., C.L., H.S.F.), Radiology (J.M.P.), Pathology (D.D.B), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC 27710 USA
2 Address correspondence to Jennifer Quinn, The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710 (quinn008{at}mc.duke.edu).
Abstract
Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent or progressive MG. Irinotecan dose escalation occurred independently within 2 strata: patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) and patients not receiving EIAEDs. BCNU was administered at a dose of 100 mg/m2 over 1 h every 6 weeks on the same day as the first irinotecan dose was administered. Irinotecan was administered intravenously over 90 min once weekly. Treatment cycles consisted of 4 weekly administrations of irinotecan followed by a 2-week rest with dose escalation in cohorts of 3 to 6 patients. Seventy-three patients were treated, including 49 patients who were on EIAEDs and 24 who were not on EIAEDs. The maximum tolerated dose for patients not on EIAEDs was 125 mg/m2. The maximum tolerated dose for patients on EIAEDs was 225 mg/m2. Dose-limiting toxicity was evenly distributed among the following organ systems: pulmonary, gastrointestinal, cardiovascular, neurologic, infectious, and hematologic, without a clear predominance of toxicity involving any one organ system. There was no evidence of increasing incidence of toxicity involving one organ system as irinotecan dose was escalated. On the basis of these results, we conclude that the recommended doses of irinotecan for a phase 2 clinical trial when given in combination with BCNU (100 mg/m2) are 225 mg/m2 for patients on EIAEDs and 125 mg/m2 for patients not on EIAEDs.
References
Castellino, R.C., Elion, G.B., Keir, S.T., Houghton, P.J., Johnson, S.P., Bigner, D.D., and Friedman, H.S. (2000) Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother. Pharmacol. 45,345 -349.[CrossRef][Web of Science][Medline]
Chang, C.H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J.S., and Tsukada, Y. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52,997 -1007.[CrossRef][Web of Science][Medline]
Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S. (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41,485 -490.[CrossRef][Web of Science][Medline]
Colvin, O.M., and Chabner, B.A. (1990) Alkylating agents. In: Chabner, B.A., and Collins, J.M. (Eds.), Cancer Chemotherapy. Principles and Practice, Chapter 11. Philadelphia: J.B. Lippincott Company, pp. 276-313.
Crews, K.R., Stewart, C.F., Jones-Wallace, D., Thompson, S.J.,
Houghton, P.J., Heideman, R.L., Fouladi, M., Bowers, D.C., Chintagumpala,
M.M., and Gajjar, A. (2002) Altered irinotecan pharmacokinetics
in pediatric high-grade glioma patients receiving enzyme-inducing
anticonvulsant therapy. Clin. Cancer Res.
8,2202
-2209.
Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20,111 -120.[CrossRef][Medline]
Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby,
T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughesy,
T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner,
D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring,
G.L., and Miller, L.L. (1999) Irinotecan therapy in adults with
recurrent or progressive malignant glioma. J. Clin.
Oncol. 17,1516
-1525.
Green, S.B., Byar, D.P., Walker, M.D., Pistenmaa, D.A., Alexander, E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., Mealey, J., Jr., Odom, G.L., Paoletti, P., Ransohoff, J., 2nd, Robertson, J.T., Selker, R.G., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. 67,121 -132.[Web of Science][Medline]
Hall, A.G., and Tilby, M.J. (1992) Mechanism of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 6, 163-173.[CrossRef][Web of Science][Medline]
Levin, V.A., Wara, W.M., Davis, R.L., Vestnys, P., Resser, K.J., Yatsko, K., Nutik, S., Gutin, P.H., and Wilson, C.B. (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg. 63,218 -223.[Web of Science][Medline]
Mathijssen, R.H., Sparreboom, A., Dumez, H., van Oosterom, A.T, and de Bruijn, E.A. (2002) Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 13,139 -140.[CrossRef][Medline]
NCI. National Cancer Institute, Cancer Therapy Evaluation Program. Common Toxicity Criteria-Version 2.0, published April 30,1999 . Cited January 5, 2004. Available at https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ctc000w$.startup.
Pourquier, P., Loktionova, N.A., Pegg, A.E., and Pommier, Y. (2000) O6-alkylation of guanine induces topoisomerase I-DNA covalent complexes in vitro and in MNNG-treated cells. Proc. Am. Assoc. Cancer Res. 41,426 (abstract).
Rideout, D.C., and Chou, T.-C. (1991) Synergism, antagonism, and potentiation in chemotherapy: An overview. In: Chou, T.-C., and Rideout, D.C. (Eds.), Synergism and Antagonism in Chemotherapy, Chapter 1. San Diego: Academic Press, pp.3 -60.
Sekikawa, T., Takano, H., Okamura, T., Sasaki, M., Kumazaki, T., and Nishiyama, M. (2000) O6-methylguanine-DNA methyltransferase is a critical determinant of cytotoxicity for DNA topoisomerase I inhibitors. Proc. Am. Assoc. Cancer Res. 41,179 (abstract).
Shapiro, W.R. (1986) Therapy of adult malignant brain tumors. What have the clinical trials taught us? Semin. Oncol. 13,38 -45.[Web of Science][Medline]
Slichenmyer, W.J., Rowinsky, E.K., Donehower, R.C., and Kaufmann,
S.H. (1993) The current status of camptothecin analogues as
antitumor agents. J. Natl. Cancer Inst.
85,271
-291.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro-oncol, January 1, 2009; 11(1): 80 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol., December 1, 2004; 22(23): 4779 - 4786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma Neuro-oncol, April 1, 2004; 6(2): 134 - 144. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
